User:Swelgemoed/effect of TMC125 on the pharmacokinetics of oral contraceptives
 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
No clinically relevant effect of TMC125 on the pharmacokinetics of oral contraceptives
Background
[edit]TMC125 is an NNRTI with potent activity against wild-type HIV-1 and HIV-1 resistant to currently approved NNRTIs. TMC125 is an inducer of CYP3A4 and an inhibitor of both CYP2C9 and 2C19, all involved in the metabolism of oral contraceptives. This study assessed the effect of TMC125 on the pharmacokinetics of ethinylestradiol and norethindrone.
Methods
[edit]The oral contraceptive Ortho-Novum® 1/35 was given for three cycles of 28 days: a run-in cycle followed by two cycles with pharmacokinetic (PK)assessments. In the third cycle, 200mg TMC125 bid (Phase III formulation) was co-administered from Day 1 to Day 15. On Day 15 of Cycles 2 and 3, the 24-hour pharmacokinetics of ethinylestradiol and norethindrone were assessed. The 12-hour pharmacokinetics of TMC125 were evaluated on Day 15 of Cycle 3. PK parameters were calculated by non-compartmental methods. The pharmacokinetics of ethinylestradiol and norethindrone were analysed using a linear, mixed-effects model. Safety and tolerability were evaluated.
Results
[edit]Thirty HIV-negative female volunteers participated (median age 24 years). When combined with TMC125, ethinylestradiol AUC24h was 122% (90% CI: 113–131%) compared with administration of oral contraceptives alone; Cmax and Cmin were 133% (90% CI: 121–146%) and 109% (90% CI: 101–118%), respectively. AUC24hr, Cmax and Cmin of norethindrone were 95% (90% CI: 90–99%), 105% (90% CI: 98–112%) and 78% (90% CI: 68–90%), respectively, when combined with TMC125 compared with administration of oral contraceptives alone. The concomitant administration of TMC125 and oral contraceptives was generally safe and well tolerated. Ten adverse events (AEs) led to trial discontinuation: seven grade 2 rashes, one grade 2 pyrexia, one grade 3 herpes simplex and one grade 2 lymphadenopathy.
Conclusions
[edit]No clinically relevant changes in the pharmacokinetics of ethinylestradiol and norethindrone were observed when TMC125 was given concomitantly with Ortho-Novum® 1/35. No loss in the efficacy of oral contraceptives are expected when TMC125 is co-administered.
Acknowledgements
[edit]The authors would like to express their gratitude to the volunteers. We also acknowledge:
- MP Bouche, J&J Pharmaceutical Research and Development, Beerse, Belgium.
- U Lorch, Richmond Pharmacology Ltd., London, UK.
References
[edit]- Vingerhoets J, et al. J Virol 2005;79:12773–82. http://www.hivandhepatitis.com/2008icr/icaac_idsa/posters/3_Kakuda.pdf
- Cohen C, et al. 16th International AIDS Conference 2006 (Poster TUPE0061). http://www.medadvocates.org/resources/conferences/idsa/2006/IDSA%2006_TMC125%20DI%20clarithromycin%20poster_22Sep06revMS.pdf
- Palovaara S, et al. Br J Clin Pharmacol 2003;56:232–7. http://jcp.sagepub.com/content/45/12/1413.abstract
- Shelepova T, et al. J Clin Pharm 2005;45:1413–21. http://dmd.aspetjournals.org/content/early/2009/05/19/dmd.109.026997.full.pdf
- Official Publication of Richmond Pharmacology Ltd Presented at the 8th International Congress on Drug Therapy in HIV infection, Glasgow, UK, 12–16 November 2006 http://www.aegis.com/conferences/hiv-glasgow/2006/P277.pdf
External links
[edit]